IL138292A - Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor - Google Patents

Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor

Info

Publication number
IL138292A
IL138292A IL13829299A IL13829299A IL138292A IL 138292 A IL138292 A IL 138292A IL 13829299 A IL13829299 A IL 13829299A IL 13829299 A IL13829299 A IL 13829299A IL 138292 A IL138292 A IL 138292A
Authority
IL
Israel
Prior art keywords
medicament
treating
preventing
aromatase inhibitor
mammary carcinoma
Prior art date
Application number
IL13829299A
Other languages
English (en)
Other versions
IL138292A0 (en
Original Assignee
S W Patentverwertungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL138292(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S W Patentverwertungs Gmbh filed Critical S W Patentverwertungs Gmbh
Publication of IL138292A0 publication Critical patent/IL138292A0/xx
Publication of IL138292A publication Critical patent/IL138292A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13829299A 1998-03-18 1999-03-03 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor IL138292A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98104949A EP0943333A1 (de) 1998-03-18 1998-03-18 Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
PCT/EP1999/001374 WO1999047143A1 (de) 1998-03-18 1999-03-03 Medikament zur prophylaxe und/oder behandlung des mammakarzinoms enthaltend einen steroidalen aromataseinhibitor

Publications (2)

Publication Number Publication Date
IL138292A0 IL138292A0 (en) 2001-10-31
IL138292A true IL138292A (en) 2005-08-31

Family

ID=8231611

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13829299A IL138292A (en) 1998-03-18 1999-03-03 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor

Country Status (19)

Country Link
EP (2) EP0943333A1 (cs)
JP (1) JP4920822B2 (cs)
KR (1) KR100778803B1 (cs)
CN (1) CN1168448C (cs)
AT (1) ATE230995T1 (cs)
AU (1) AU751040B2 (cs)
BR (1) BR9908885A (cs)
CA (1) CA2324077C (cs)
CZ (1) CZ292643B6 (cs)
DE (1) DE59904042D1 (cs)
DK (1) DK1063998T3 (cs)
ES (1) ES2190201T3 (cs)
HU (1) HU226105B1 (cs)
ID (1) ID26965A (cs)
IL (1) IL138292A (cs)
PL (1) PL343100A1 (cs)
RU (1) RU2225206C2 (cs)
SK (1) SK285349B6 (cs)
WO (1) WO1999047143A1 (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042411A1 (de) * 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Exemestan
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
RU2297798C1 (ru) * 2005-10-03 2007-04-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук ГУ НИИ онкологии ТНЦ СО РАМН Способ комплексного лечения резектабельных форм рака эндометрия
RU2363466C2 (ru) * 2007-03-29 2009-08-10 АО Ефаг Способ и набор для лечения и профилактики злокачественных опухолей женской репродуктивной системы с применением 9-оксоакридин-10-уксусной кислоты, и/или ее соли, и/или ее сложного эфира
JP4524296B2 (ja) * 2007-03-30 2010-08-11 生化学工業株式会社 発毛促進剤
DE102007032468A1 (de) 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
RU2396942C2 (ru) * 2008-08-01 2010-08-20 Владимир Борисович Деев Лекарственная композиция для лечения доброкачественных новообразований на коже
TR201816243T4 (tr) 2011-01-31 2018-11-21 Lucolas M D Ltd Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
US20130309217A1 (en) * 2011-01-31 2013-11-21 Lucolas-M.D. Ltd. Cosmetic use
US11850451B2 (en) 2011-01-31 2023-12-26 Lucolas-M.D. Ltd. Cosmetic compositions and methods for improving skin conditions
EP3666276A1 (en) * 2018-12-14 2020-06-17 dcic Biopharmaceutical Limited Medication against estrogen-receptor beta (erbeta) positive breast tumor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
DE3322285A1 (de) * 1983-06-18 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
JPS6345294A (ja) * 1986-04-07 1988-02-26 Shionogi & Co Ltd アロマタ−ゼ阻害ステロイド誘導体
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
GB2231568B (en) * 1989-03-31 1992-07-08 Farmos Oy New aromatase inhibiting 4(5)-imidazoles
GB2229719B (en) * 1989-03-30 1992-04-29 Farmos Oy Novel aromatase inhibiting 4(5)-imidazoles
FR2656310B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveaux produits sterouides comportant en position 10, un radical thioethyle substitue, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
DE4039559A1 (de) * 1990-12-07 1992-06-11 Schering Ag Funktionalisierte vinylazole, verfahren zu deren herstellung, pharmazeutische praeparate die diese vinylazole enthalten sowie deren verwendung zur herstellung von arzneimitteln
GB9212833D0 (en) * 1992-06-17 1992-07-29 Glaxo Group Ltd Chemical compounds
ATE201403T1 (de) * 1993-03-16 2001-06-15 Pfizer Naphtalinderivate
JPH07215992A (ja) * 1993-12-07 1995-08-15 Teikoku Hormone Mfg Co Ltd ６−又は７−置換アンドロスタ−１，４−ジエン誘導体
US6020327A (en) * 1994-09-14 2000-02-01 The Central Sheffield University Hospitals Nhs Trust Control of hair growth
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
WO1997036570A1 (de) * 1996-03-29 1997-10-09 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite'
EP0930876B2 (en) * 1996-07-22 2010-07-07 Renovo Limited Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds

Also Published As

Publication number Publication date
HUP0101005A2 (hu) 2001-08-28
DK1063998T3 (da) 2003-05-12
AU3143499A (en) 1999-10-11
PL343100A1 (en) 2001-07-30
ID26965A (id) 2001-02-22
CZ292643B6 (cs) 2003-11-12
KR100778803B1 (ko) 2007-11-27
CN1301165A (zh) 2001-06-27
EP1063998A1 (de) 2001-01-03
BR9908885A (pt) 2000-11-21
SK13422000A3 (sk) 2001-05-10
CA2324077C (en) 2008-07-29
CA2324077A1 (en) 1999-09-23
IL138292A0 (en) 2001-10-31
SK285349B6 (sk) 2006-11-03
CN1168448C (zh) 2004-09-29
WO1999047143A1 (de) 1999-09-23
EP1063998B1 (de) 2003-01-15
HU226105B1 (en) 2008-04-28
CZ20003256A3 (cs) 2001-04-11
JP2002506823A (ja) 2002-03-05
ES2190201T3 (es) 2003-07-16
RU2225206C2 (ru) 2004-03-10
DE59904042D1 (de) 2003-02-20
JP4920822B2 (ja) 2012-04-18
ATE230995T1 (de) 2003-02-15
EP0943333A1 (de) 1999-09-22
KR20010034603A (ko) 2001-04-25
AU751040B2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
AU2003274823A1 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
PL343100A1 (en) Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
MY164077A (en) Compositions and uses of et743 for treating cancer
FR2791573B1 (fr) Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
AU2949889A (en) Reverse transcriptase inhibitors for treating adenocarcinomas
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
GB0008172D0 (en) Therapy
IL124881A0 (en) Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
BR0111740A (pt) Terapia combinada contra tumores que compreende derivados de distamicina acriloila substituìda e agentes de alquilação
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.
WO2001036048A8 (en) Phorboxazole derivatives for treating cancer
CY1109852T1 (el) Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη
KR920700636A (ko) 인체의 악성 종양을 치료하기 위한 1,2-벤조피론 유도체의 용도
ZA97215B (en) Use of the i-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
IT1314187B1 (it) Combinazione di differenti composizioni farmaceutiche per iltrattamento del carcinoma mammario e relativo uso
AU3145400A (en) Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer
HK1013263A (en) Use of taxol for treating lymphomas and breast cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
EXP Patent expired